TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (refers to “transient conjugation”) to create best-in-class products to address unmet patient needs.
About TransConTM Technology
TransCon refers to “transient conjugation.” The proprietary TransCon technology platform is an innovative approach to creating new therapies that combine the benefits of prodrug and sustained-release technologies to optimize therapeutic effect, including efficacy, safety and dosing frequency.
TransCon technologies are designed to solve the fundamental limitations of current treatment approaches by extending the duration of a drug’s action in the body and optimizing the overall risk/benefit profile of a given therapeutic.
TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable-release manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained.
TransCon technologies can be applied broadly to a protein, peptide or small molecule in multiple therapeutic areas. Depending on the type of carrier used, TransCon prodrugs can also be designed to act systemically or locally.
TransCon Technology: Sustained Systemic Delivery
TransCon Technology: Sustained Localized Delivery